US EditionPfizer amps up push into obesity treatments with $4.9B deal for Metsera
Pfizer aims to strengthen its obesity drug portfolio by acquiring Metsera for up to $7.3 billion amid growing competition and an obesity market projected to exceed $100 billion.
- Pfizer Inc. will acquire Metsera Inc. for $4.9 billion to enhance its presence in the obesity market after facing setbacks with its own weight-loss medications.
- Metsera's portfolio includes next-generation obesity treatments, including a drug that showed significant weight loss in a study, allowing patients to lose up to 8.4% of their weight.
- The obesity market is projected to reach $100 billion by 2030, prompting Pfizer to expand through acquisitions to compete with established rivals.
- The acquisition deal is expected to be completed by the end of the fourth quarter of 2025, according to Pfizer and Metsera's statements.
131 Articles
131 Articles
The US laboratory Pfizer will buy Metsera, a manufacturer of drugs for obesity and heart disease, for $4.9 billion, announced companies on Monday. With the acquisition, Pfizer seeks to expand its portfolio by entering the gigantic market for anti-obesity treatments. “Obesity is a broad and growing field, with more than 200 associated health conditions,” said Pfizer’s executive director, Albert Bourla, in the statement. “Metsera’s acquisition pro…
Radio-Canada
Pfizer will buy the Biotech Metera for at least $4.9 billion, taking over its developing treatments for obesity.
Conservative Review
The BlazePfizer sets sights on new obesity drug market in multibillion-dollar acquisition
A little more than five months after Pfizer discontinued development of its weight-loss drug known as danuglipron, the drugmaker announced its plan on Monday to acquire a biopharmaceutical company for close to $5 billion. Pfizer published a press release on Monday confirming the unanimous agreement to acquire Metsera, a "clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic disease…
Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More
Pfizer is acquiring Metsera and its pipeline of obesity medications that could offer dosing and tolerability advantages for patients as well as a manufacturing edge for the pharma giant. Key data Phase 2 readouts for Metsera’s lead GLP-1 drug candidate are expected in 2026. The post Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More appeared first on MedCity News.
Pfizer to buy Metsera for $4.9 billion in obesity drug bet
Karen Leigh, Madison Muller and Damian Garde (Bloomberg) — Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US drugmaker agreed to buy Metsera for $47.50 in cash per share, and further payments of up to $22.50 per share if three specific and regulatory milestones are met, it said Monday, with a total potential value o…
Pfizer will buy Metsera biotechnology company for at least $4.9 billion, having access to its development treatments against obesity, the two American companies announced in a joint communiqué, reports...
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
